The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration Database
Open accessAbstract
Objective.: To present any congenital anomalies with respect to tumor necrosis factor (TNF) antagonists reported to the US Food and Drug Administration (FDA) to determine if there are common findings. Methods.: A review of the FDA database of reported adverse events with etanercept, infliximab, and adalimumab from 1999 through December of 2005 was performed. Key words for congenital anomalies were employed as search tools. Duplicate reports were eliminated. Any concomitant medicines were recorded. Results.: Our review of > 120,000 adverse events revealed a total of 61 congenital anomalies in 41 children born to mothers taking a TNF antagonist. Of these mothers, 22 took etanercept and 19 took infliximab. There were no reports in women taking adalimumab. The most common reported congenital anomaly was some form of heart defect. Twenty-four of the 41 (59%) children had one or more congenital anomalies that are part of vertebral abnormalities, anal atresia, cardiac defect, tracheoesophageal, renal, and limp abnormalities (VACTERL) association. There were 34 specific types of congenital anomalies in total, and 19 (56%) of those are part of the VACTERL spectrum. Nine of these 19 (47%) types of VACTERL anomalies were observed statistically significantly more than historical controls (p < 0.01); in 4 of these 9 the p value was ≤ 0.0001. Thirteen (32%) of the children had more than one congenital anomaly; 7 of these 13 children had 2 defects that are part of the VACTERL spectrum. However, only 1 child was diagnosed with VACTERL. In 24/41 cases (59%) the mother was taking no other concomitant medications. Conclusion.: A seemingly high number of congenital anomalies that are part of the VACTERL spectrum have been reported. These congenital anomalies are occurring at a rate higher than historical controls. This commonality raises concerns of a possible causative effect of the TNF antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Idiopathic Dilated Cardiomyopathy
Dec, G. W., & Fuster, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412083312307 · Cited by 963
A short history of thalidomide embryopathy
Lenz, W. (1988) · Teratology · doi:10.1002/tera.1420380303 · Cited by 784
MATERNAL VALPROIC ACID AND CONGENITAL NEURAL TUBE DEFECTS
Robert, E., & Guibaud, P. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90908-4 · Cited by 539
Katz, J. A., Antoni, C., Keenan, G. F., Smith, D. E., Jacobs, S. J., & Lichtenstein, G. R. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30186.x · Cited by 463
Distler, J. H. W., Jüngel, A., Huber, L. C., Schulze‐Horsel, U., Zwerina, J., Gay, R. E., Michel, B. A., Hauser, T., Schett, G., Gay, S., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22314 · Cited by 383
An IgG‐transporting Fc receptor expressed in the syncytiotrophoblast of human placenta
Simister, N. E., Story, C. M., Chen, H., & Hunt, J. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260718 · Cited by 332
Verification of the fetal valproate syndrome phenotype
Ardinger, H. H., Atkin, J. F., Blackston, R. D., Elsas, L. J., Clarren, S. K., Livingstone, S., Flannery, D. B., Pellock, J. M., Harrod, M. J., Lammer, E. J., et al. (1988) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320290123 · Cited by 302
Lammer, E. J., Sever, L. E., & Oakley, G. P. (1987) · Teratology · doi:10.1002/tera.1420350319 · Cited by 291
Vasiliauskas, E. A., Church, J. A., Silverman, N., Barry, M., Targan, S. R., & Dubinsky, M. C. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.07.018 · Cited by 268
Mahadevan, U., Kane, S., Sandborn, W. J., Cohen, R. D., Hanson, K., Terdiman, J. P., & Binion, D. G. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02405.x · Cited by 260
Cited by
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Guidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 769
Mahadevan, U., Wolf, D. C., Dubinsky, M., Cortot, A., Lee, S. D., Siegel, C. A., Ullman, T., Glover, S., Valentine, J. F., Rubin, D. T., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.11.011 · Cited by 498
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D. A., Finlay, A. Y., Griffiths, C. E. M., Jackson, K., McHugh, N. J., et al. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09505.x · Cited by 464
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A., Koo, J. Y. M., Lebwohl, M., Leonardi, C. L., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.055 · Cited by 460
Metadata
- Authors
- CARTER, J. D., LADHANI, A., RICCA, L. R., VALERIANO, J., & VASEY, F. B.
- Venue
- The Journal of Rheumatology
- Publisher
- The Journal of Rheumatology
- Published
- 2009-03
- Volume
- 36
- Issue
- 3
- Pages
- 635-641
- ISSN
- 0315-162X (ISSN-L)
- 1499-2752
- OpenAlex
- W2038763425
- Cited by
- 256
- References
- 34
- FWCI
- 35.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration Database. https://app.cochat.ai/papers/10.3899/jrheum.080545
- The paper
- CARTER, J. D., LADHANI, A., RICCA, L. R., VALERIANO, J., & VASEY, F. B. (2009). A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration Database. The Journal of Rheumatology. https://doi.org/10.3899/jrheum.080545
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.